HR 10887
  • Introduced
    Oct 22, 2026
  • Passed House
  • Passed Senate
  • Became Law
HR 10887
United States House Bill
Did you know we offer free bill tracking in Congress and 50 states, AI tools to streamline your work, and a great mobile app? Sign up here
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Last Action See all actions
House • Oct 22, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Latest Bill Text See all bill texts
Introduced in House

Summary

Comments on HR 10887

Tweets

Whip Lists

Sponsors
Votes
Looks like there aren't any voting records available at this moment.
Actions
  • Oct 22, 2026 | House
    • Introduced in House
    • Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill Texts
Documents
Looks like we don't have any documents available at this moment.
Sources